Drug Trial Radar · NCT04718181
Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Mar 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
131
Actual
Start
Feb 1, 2021
Primary completion
Jan 28, 2023
Study completion Jan 28, 2023
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The study is a randomized, single oral dose, crossover study in up to three parts to investigate the relative bioavailability and bioequivalence of two different formulations of risdiplam 5 mg (dispersible tablets) versus the current risdiplam oral solution formulation in healthy male and female participants. The effect of food on these two dispersible tablets and the current oral solution will be studied, as well as the effect of omeprazole on the dispersible tablets.
Conditions
- Muscular Atrophy, Spinal
Interventions
risdiplamDrug
Risdiplam will be administered orally at a single dose of 5 mg in different formulations. Dispersible tablet formulations (F21/F22) will be administered as swallowed tablet or as tablet dispersed in water. The powder for constitution to an oral solution will be administered as an oral solution constituted with purified water.
omeprazoleDrug
Omeprazole will be administered orally as a capsule at a dose of 40 mg per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Plasma Concentration of Risdiplam in Cohorts A and BTime frame: Day 1 to Day 7 in Periods 1-5
- Part 1: Plasma Concentration of Risdiplam in Fed and Fasted States in Cohort ETime frame: Day 1 to Day 7 in Period 1 and Period 2
- Part 1: Plasma Concentration of Risdiplam in Cohorts C and DTime frame: Period 1: Day 1 to Day 7; Period 2: Day 1 to Day 13
- Parts 2 and 3: Plasma Concentration of RisdiplamTime frame: Day 1 to Day 11 in Periods 1-4
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Daytona Beach Clinical Rsch Unit
Daytona Beach, Florida
QPS- Springfield
Springfield, Missouri
Dallas Clinical Research Unit
Dallas, Texas
Covance Clinical Research Unit, Inc
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.